SEC Form 4 · accession 0001193125-26-308922
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William P Forbes
Officer — EVP, Chief Development Officer
Period of report
Jul 19, 2026
Accepted (ET)
Jul 20, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 19, 2026 | M | 3,874 | — | A | 225,485 | D | |
| Common Stock | Jul 19, 2026 | F | 1,101 | $0.47 | D | 224,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jul 19, 2026 | M | 3,874 | D | — | — | Common Stock | 3,874 | 23,246 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).